In utero exposure to diethylstilbestrol (DES) does not increase genomic instability in normal or neoplastic breast epithelium

Cancer

Volumn 107, Issue 9, 2006, Pages 2122-2126

  Larson, Pamela S ^a   Ungarelli, Rosemarie A ^b   De Las Morenas, Antonio ^a   Cupples, L Adrienne ^c   Rowlings, Kathleen ^d   Palmer, Julie R ^d,e   Rosenberg, Carol L ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d BOSTON UNIVERSITY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Allele imbalance; Breast cancer; Diethylstilbestrol; Genetic instability; In utero exposure; Loss of heterozygosity; Microsatellite; Prenatal

Indexed keywords

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST EPITHELIUM; BREAST HYPERPLASIA; CANCER INVASION; CANCER RISK; CARCINOMA IN SITU; CHROMOSOME 9; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENOMIC INSTABILITY; HEALTH CARE ORGANIZATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROSATELLITE INSTABILITY; PRENATAL EXPOSURE; PRIORITY JOURNAL;

ADULT; AGE OF ONSET; ALLELIC IMBALANCE; BREAST NEOPLASMS; CARCINOMA; DIETHYLSTILBESTROL; ESTROGENS, NON-STEROIDAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOSS OF HETEROZYGOSITY; MAMMARY GLANDS, HUMAN; MATERNAL EXPOSURE; MICROSATELLITE INSTABILITY; MIDDLE AGED; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; REFERENCE VALUES;

EID: 33750532516     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22223     Document Type: Article

References (36)

1. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina, association of maternal stilbestrol therapy with tumor appearance in young women. New Eng J Med. 1971;284:878-881.
2. Marselos M, Tomatis L. Diethylstilbestrol: II, pharmacology, toxicology and carcinogenicity in experimental animals. Eur J Cancer. 1992;29A:149-155.
3. Giusti RM, Iwamoto K, Hatch EE. Diethylstilbestrol revisited: a review of the long-term health effects. Ann Int Med. 1995;122:778-788.
4. Baird DD, Newbold R. Prenatal diethylstilbestrol (DES) exposure is associated with uterine leiomyoma development. Reprod Toxicol 2005;20:81-84.
5. Miki Y, Suzuki T, Tazawa C, et al. Analysis of gene expression induced by diethylstilbestrol (DES) in human primitive Mullerian duct cells using microarray. Cancer Lett. 2005;220:197-210.
6. Huang WW, Yin Y, Bi Q, et al. Developmental diethylstilbestrol exposure alters genetic pathways of uterine cytodifferentiation. Mol Endocrinol. 2005;19:669-682.
7. Hatch EE, Palmer JR, Titus-Ernstoff L, et al. Cancer risk in women exposed to diethylstilbestrol in utero. JAMA. 1998;280:630-634.
8. Palmer JR, Hatch EE, Rosenberg CL, et al. Risk of breast cancer in women exposed to diethylstilbestrol in utero: preliminary results (United States). Cancer Causes Control. 2002;13: 753-758.
9. Palmer JR, Wise LA, Hatch EE, et al. Prenatal diethylstilbestrol exposure and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:1509-1514.
10. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Eng J Med. 2006;354:270-282.
11. Lee YR, Park J, Yu HN, Kim JS, Youn HJ, Jung SH. Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells. Biochem Biophys Res Commun. 2005;336:1221-1226.
12. Razandi M, Pedram A, Levin ER. Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Mol Endocrinol. 2000;14:1434-1447.
13. Fernandez SV, Russo I, Russo J. Estradiol and its metabolites 4-hydroxyestradiol and 2-hydroxyestradiol induce mutations in human breast epithelial cells. Int J Cancer. 2006;118:1862-1868.
14. Fernandez SV, Russo I, Lareef M, Balsara B, Russo J. Comparative genomic hybridization of human breast epithelial cells transformed by estrogen and its metabolites. Int J Oncol. 2005;26:691-695.
15. Wheeler WJ, Hsu TC, Tousson A, Brinkley BR. Mitotic inhibition and chromosome displacement induced by estradiol in Chinese hamster cells. Cell Motil Cytoskeleton. 1987;7:235-247.
16. Wheeler WJ, Cherry L, Downs T, Hsu TC. Mitotic inhibition and aneuploidy induction by naturally occurring and synthetic estrogens in Chinese hamster cells in vitro. Mutat Res. 1986;171:31-41.
17. Li JJ, Hou X, Banerjee SK, et al. Overexpression and amplification of c-myc in the Syrian hamster kidney during estrogen carcinogenesis: a probable critical role in neoplastic transformation. Cancer Res. 1999;59:2340-2346.
18. Boyd J, Takahashi H, Waggoner SE, et al. Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero. Cancer. 1996;77:507-513.
19. Kabbarah O, Mallon M, Pfeifer JD, Edelmann W, Kucherlapati R, Goodfellow PJ. A panel of repeat markers for detection of microsatellite instability in murine tumors. Mol Carcinog. 2003;38:155-159.
20. Green M, Wilson C, Newell O, Sadrud-Din S, Thomas R. Diallyl sulfide inhibits diethylstilbestrol-induced DNA adducts in the breast of female ACI rats. Food Chem Tox. 2005;43:1323-1331.
21. Page DL, Rogers L. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Human Pathol. 1992;23:1095-1097.
22. Elston CW, Ellis I. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
23. Raju U, Crissman J, Zarbo RJ, Gottieb C. Epitheliosis of the breast. An immunohistochemical characterization and comparison to malignant intraductal proliferations of the breast. Am J Surg Pathol. 1990;14:939-947.
24. Rosai J. Borderline epithelial lesions of the breast. Am J Surg Pathol. 1991;15:209-221.
25. Wells WA, Carney P, Eliassen MS, Grove MR, Tosteson AN. Pathologists' agreement with experts and reproducibility of breast ductal carcinoma-in-situ classification schemes. Am J Pathol. 2000;24:651-659.
26. Larson RS, de las Morenas A, Bernett SN, Cupples LA, Rosenberg CL. Loss of heterozygosity (LOH), or allele imbalance (AI), in histologically normal breast epithelium is distinct from LOH or AI in co-existing cancers. Am J Pathol. 2002;161:283-290.
27. Schlechter BL, Yang Q, Larson PS, et al. Quantitative DNA fingerprinting may distinguish new primary breast cancer from disease recurrence. J Clin Oncol. 2004;22:1830-1838.
28. Kerangueven F, Noguchi T, Coulier F, et al. Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res. 1997;57:5469-5474.
29. O'Connell P, Pekkel V, Fuqua SAW, Osborne CK, Clark GM, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst. 1998;90:697-703.
30. Osborne RJ, Hamshere M. A genome-wide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer. Cancer Res. 2000;60:3706-3712.
31. Shen CY, Yu JC, Lo YL, et al. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res. 2000;60:3884-3892.
32. Cornelisse CJ, Kuipers-Dijkshoorn N, van Vliet M, Hermans J, Devilee P. Fractional allelic imbalance in human breast cancer increases with tetraploidization and chromosome loss. Int J Cancer. 1992;50:544-548.
33. Fujii H, Marsh C, Cairns P, Sidransky D, Gabrielson E. Genetic divergence in the clonal evolution of breast cancer. Cancer Res. 1996;56:1493-1497.
34. Anbazhagan R, Fujii H, Gabrielson E. Microsatellite instability is uncommon in breast cancer. Clin Cancer Res. 1999;5:839-844.
35. Kodama M, Kodama T. The nature of tamoxifen action in the control of female breast cancer. In Vivo. 2001;15:319-325. [Review].
36. Mills LH, Lee AJ, Parlow AF, Zhu BT. Preferential growth stimulation of mammary glands over uterine endometrium in female rats by a naturally occurring estradiol-17beta-fatty acid ester. Cancer Res. 2001;61:5764-5770.